Insight Molecular Diagnostics (IMDX) Net Cash Flow (2015 - 2026)

Insight Molecular Diagnostics has disclosed Net Cash Flow across 12 years of filings, most recently posting $16.4 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $16.4 million, down 26.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 112.8% YoY), and the FY2025 annual result was $2.7 million, up 450.13% from the prior year.
• Net Cash Flow came in at $16.4 million for Q1 2026 at Insight Molecular Diagnostics, up from -$7.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $24.4 million in Q2 2022 to a low of -$15.2 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$4.4 million (2023), against an average of -$458588.2.
• Across the five-year window, Net Cash Flow slumped 304.27% in 2022 and jumped 681.53% in 2025, its largest moves.
• Insight Molecular Diagnostics' Net Cash Flow stood at -$10.5 million in 2022, then soared by 58.76% to -$4.4 million in 2023, then soared by 221.26% to $5.3 million in 2024, then plunged by 237.91% to -$7.3 million in 2025, then surged by 326.03% to $16.4 million in 2026.
• The last three Net Cash Flow figures came in at $16.4 million (Q1 2026), -$7.3 million (Q4 2025), and -$5.7 million (Q3 2025), per Business Quant data.